Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Anaptysbio Inc (NQ: ANAB ) 37.32 -0.43 (-1.14%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 262,705 Open 38.26 Bid (Size) 15.00 (1) Ask (Size) 38.00 (1) Prev. Close 37.75 Today's Range 36.86 - 38.33 52wk Range 13.36 - 41.31 Shares Outstanding 27,433,359 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why AnaptysBio Was Such a Healthy Stock This Week August 23, 2024 The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor. Via The Motley Fool Insiders Buying Yum China And 2 Other Stocks August 19, 2024 Via Benzinga Performance YTD +71.98% +71.98% 1 Month +0.86% +0.86% 3 Month +59.76% +59.76% 6 Month +41.04% +41.04% 1 Year +85.86% +85.86% More News Read More UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday August 14, 2024 Via Benzinga AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering August 14, 2024 Via Investor's Business Daily S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday August 14, 2024 Via Benzinga Topics ETFs Economy Stocks Exposures Interest Rates US Equities 4 Analysts Assess AnaptysBio: What You Need To Know August 06, 2024 Via Benzinga The Analyst Landscape: 7 Takes On AnaptysBio May 10, 2024 Via Benzinga Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering August 14, 2024 From AnaptysBio, Inc. Via GlobeNewswire ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 August 05, 2024 Via InvestorPlace Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update August 05, 2024 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst July 22, 2024 Via Benzinga Unveiling 4 Analyst Insights On AnaptysBio April 01, 2024 Via Benzinga ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire BTIG Research Predicts Over 118% Rally for These 3 Stocks April 15, 2024 Via InvestorPlace Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week April 12, 2024 Via The Motley Fool Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 11, 2024 Via Benzinga Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday April 11, 2024 Via Benzinga Topics Stocks Exposures US Equities Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers March 12, 2024 Via Benzinga Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 11, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting February 29, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference January 31, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals November 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
